Compare THRY & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | THRY | FATE |
|---|---|---|
| Founded | 2012 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 114.8M | 125.6M |
| IPO Year | 2020 | 2013 |
| Metric | THRY | FATE |
|---|---|---|
| Price | $3.18 | $1.35 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $9.33 | $4.10 |
| AVG Volume (30 Days) | 502.2K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.50 | 29.88 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $785,015,000.00 | $6,646,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $339.00 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.91 | $0.91 |
| 52 Week High | $15.49 | $1.94 |
| Indicator | THRY | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 50.76 | 55.22 |
| Support Level | $2.46 | $0.95 |
| Resistance Level | $3.69 | $1.45 |
| Average True Range (ATR) | 0.21 | 0.09 |
| MACD | 0.06 | 0.01 |
| Stochastic Oscillator | 49.70 | 65.63 |
Thryv Holdings Inc is dedicated to supporting local, independent service-based businesses and emerging franchises by providing a cloud-based software platform, and marketing solutions to entrepreneurs. The group are provider of SaaS all-in-one small business management software in addition to providing print and digital marketing solutions to SMBs. Its solutions enable small and medium-sized business clients to attract and generate new business leads, manage their customer relationships efficiently with artificial intelligence (AI) tools and automation. The group has two business segments; Thryv SaaS deriving maximum revenue and Thryv Marketing Services.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.